Search Results - Felip Font, E

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    6ER-021 Evaluation of COVID mortality during hospital admission in patients receiving oncological treatment

    6ER-021 Evaluation of COVID mortality during hospital admission in patients receiving oncological treatment by Serramontmany Morante, E, Cardona-Pascual, I, Garcia Ortega, P, Carreras Soler, M, Gorgas Torner, MQ, Cidoncha Muñoz, I, Felip Font, E

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population

    127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-... by Garon, E.G, Rizvi, N.A, Leighl, N.B, Hui, R, Eder, J.P, Patnaik, A, Aggarwal, C, Horn, L, Balmanoukian, A.S, Gubens, M.A, Felip-Font, E, Costa, E. Carceny, Soria, J.C, Ahn, M.J, Arkenau, H.T, Lee, J.S, Robinet, G, Lubiniecki, G.M, Zhang, J, Emancipator, K, Rutledge, R, Dolled-Filhart, M, Gandhi, L

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)

    103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) by Andric, Z.G., Gálffy, G., Dols, M. Cobo, Szima, B., Stojanovic, G., Petrovic, M.D., Font, E. Felip, Baz, D. Vicente, Aix, S. Ponce, Juan-Vidal, O., Tehenes, S., Szalai, Z., Losonczy, G., Blanco, A. Calles, Bernabe, R., Duecker, K., Zhou, D., Schroeder, A., Guezel, G., Ciardiello, F.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    219P Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT)

    219P Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT) by Cedres, S., Amair, F., Martinez-Marti, A., Navarro, A., Pardo, N., Remon-Masip, J., Miquel, J.M., Villacampa, G., Dienstmann, R., Font, E. Felip

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT): 219P

    Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT): 219P by Cedres, S, Amair, F, Martinez-Marti, A, Navarro, A, Pardo, N, Remon-Masip, J, Miquel, J M, Villacampa, G, Dienstmann, R, Font, Felip E

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Phase II study of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC)

    Phase II study of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC) by Santome, L., Felip, E., Rosell, R., Domine, M., Font, A., Garrido, P., Carrato, A., Terrasa, J., Mañe, J., Baselga, J.

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Preliminary results of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC): A phase II study

    Preliminary results of sequential dose-dense paclitaxel followed by topotecan in extensive small-cell lung cancer (SCLC): A phase II study by Felip, E, Font, A, Rosell, R, Garrido, P, Carrato, A, Terrasa, S, Mane, J, Santome, L, Baselga, J

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: